

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (01-08)

Approved for use through 03/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,098
				Filing Date	May 19, 2006
				First Named Inventor	Adam McCluskey
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	65617US(54086)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Ben-Bassat et al., Tyrosine Kinase Inhibitors Suppress the Growth of Non-Hodgkin B Lymphomas, 2002, Vol. 303, No. 1, pgs. 163-171.	
	CB	Mazumder, et al., Effects of Tyrophostins, Protein Kinase Inhibitors, on Human Immunodeficiency Virus Type 1 Integrase, Biochemistry, 1995, Vol. 34, pgs. 15111-15122.	
	CC	Yuan et al., QSAR development to describe HIV-1 integrase inhibition, Journal of Molecular Structure (Theochem), 529, (2000), pgs. 273-282.	
	CD	Yuan, Hongbin and Parrill, Abby, QSAR Studies of HIV-1 Integrase Inhibition, Bioorganic and Medicinal Chemistry, (2002), Vol. 10, pgs. 4169-4183.	
	CE	John, Von Hanns, Chinolinderivate, XIII Abbau der 6-Methoxy-chinolin-4-carbonsauro, Mitteilungen aus der Chem. Abt. des Deutschen Hygienischen Institutes zu Prag, September 1930, pgs. 180-189.	
	CF	John, Von Hanns, Chinolinderivate XIV Derivate der Chininsaure und Xanthochinsaure, Mitteilungen aus der Chem. Abt. des Deutschen Hygienischen Institutes zu Prag, September 1930, pgs. 190-200.	

Examiner Signature	/Walter Webb/	Date Considered	05/20/2008
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.